BMY

Bristol Myers Squibb (BMY)

Bristol Myers Squibb Co

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NYSE:BMY

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/05/11	05 : 30	Business Wire	Bristol Myers Squibb Provides Update on Phase 3 CheckMate -73L Trial	NYSE:BMY	Bristol Myers Squibb Co
2024/05/07	19 : 59	Business Wire	Bristol Myers Squibb to Participate in Upcoming Investor Conferences	NYSE:BMY	Bristol Myers Squibb Co
2024/05/06	19 : 59	Business Wire	European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite...	NYSE:BMY	Bristol Myers Squibb Co
2024/05/06	19 : 59	Business Wire	U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Application for Subcutaneous Nivolumab (nivolumab and hyaluronidase)	NYSE:BMY	Bristol Myers Squibb Co
2024/05/01	21 : 00	GlobeNewswire Inc.	Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration	NYSE:BMY	Bristol Myers Squibb Co
2024/04/29	19 : 00	PR Newswire (US)	Repertoire® Immune Medicines and Bristol Myers Squibb Announce Multi-Year Strategic Collaboration to Develop Tolerizing Vaccines for Autoimmune Diseases	NYSE:BMY	Bristol Myers Squibb Co
2024/04/26	19 : 59	Business Wire	CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb’s Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma	NYSE:BMY	Bristol Myers Squibb Co
2024/04/25	20 : 53	IH Market News	U.S. Futures Drop in Pre-Market Trading as Tech Stocks Plunge After Meta Issues Gloomy Forecast	NYSE:BMY	Bristol Myers Squibb Co
2024/04/25	19 : 59	Business Wire	Bristol Myers Squibb Reports First Quarter Financial Results for 2024	NYSE:BMY	Bristol Myers Squibb Co
2024/04/23	20 : 25	IH Market News	Apple Loses Market Share in China, GM Surges in Pre-Market Following Upward Revisions for 2024 Projections, and More News	NYSE:BMY	Bristol Myers Squibb Co
2024/04/22	19 : 59	Business Wire	Bristol Myers Squibb and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement for the Manufacture of CAR T Cell Therapies to Bring the Promise of Cell Therapy to More Patients, Faster	NYSE:BMY	Bristol Myers Squibb Co
2024/04/22	19 : 59	Business Wire	Bristol Myers Squibb and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement for the Manufacture of CAR T Cell Therapies to Bring the Promise of Cell Therapy to More Patients, Faster	NYSE:BMY	Bristol Myers Squibb Co
2024/04/09	00 : 30	Business Wire	KRAZATI (adagrasib) in Combination with Cetuximab Demonstrates Clinically Meaningful Activity as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)	NYSE:BMY	Bristol Myers Squibb Co
2024/04/07	02 : 15	Business Wire	Bristol Myers Squibb Presents New Interim Long-Term Efficacy Data from the EMERGENT-4 Trial Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society	NYSE:BMY	Bristol Myers Squibb Co
2024/04/07	02 : 15	Business Wire	Bristol Myers Squibb Presents New Pooled Interim Long-Term Safety and Metabolic Outcomes Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society	NYSE:BMY	Bristol Myers Squibb Co
2024/04/05	22 : 05	Business Wire	U.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy	NYSE:BMY	Bristol Myers Squibb Co
2024/04/03	09 : 08	Business Wire	European Commission Expands Approval of Bristol Myers Squibb’s Reblozyl® (luspatercept) to Include First-Line Treatment of Transfusion-Dependent Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (LR-MDS)	NYSE:BMY	Bristol Myers Squibb Co
2024/04/02	19 : 59	Business Wire	Bristol Myers Squibb Releases 2023 Environmental, Social and Governance Report Demonstrating Progress and Setting New Long-Term Goals	NYSE:BMY	Bristol Myers Squibb Co
2024/03/29	05 : 05	Business Wire	Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung…	NYSE:BMY	Bristol Myers Squibb Co
2024/03/29	05 : 01	Business Wire	Bristol Myers Squibb Provides Update on the First Phase 3 YELLOWSTONE Trial Evaluating Oral Zeposia (ozanimod) in Patients with Moderate to Severe Active Crohn’s Disease	NYSE:BMY	Bristol Myers Squibb Co
2024/03/28	20 : 30	GlobeNewswire Inc.	Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial Results	NYSE:BMY	Bristol Myers Squibb Co
2024/03/27	03 : 25	Business Wire	A Bristol Myers Squibb Expande as Iniciativas de Doações para a Equidade em Saúde a fim de Melhorar os Resultados de Saúde	NYSE:BMY	Bristol Myers Squibb Co
2024/03/26	19 : 59	Business Wire	Bristol Myers Squibb Expands Health Equity Grant Initiatives to Improve Health Outcomes	NYSE:BMY	Bristol Myers Squibb Co
2024/03/25	21 : 00	Business Wire	Bristol Myers Squibb to Present Data at the American College of Cardiology Annual Scientific Session 2024 Reinforcing Extensive Body of Evidence in Clinical and Real-World Settings Across Cardiovascular Portfolio	NYSE:BMY	Bristol Myers Squibb Co
2024/03/21	05 : 45	Business Wire	Bristol Myers Squibb’s Abecma (idecabtagene vicleucel) Becomes First CAR T Cell Therapy Approved in the European Union in Earlier Lines for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma	NYSE:BMY	Bristol Myers Squibb Co
2024/03/20	19 : 59	Business Wire	Bristol Myers Squibb Announces CheckMate -9DW Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Meets Primary Endpoint of Overall Survival for the First-Line Treatment of Advanced Hepatocellular Carcinoma	NYSE:BMY	Bristol Myers Squibb Co
2024/03/19	19 : 59	Business Wire	Bristol Myers Squibb and Ted Danson Empower Those with Plaque Psoriasis to Take Action in “SO, Have You Found It?” Campaign	NYSE:BMY	Bristol Myers Squibb Co
2024/03/18	21 : 44	Business Wire	Bristol Myers Squibb Completes Acquisition of Karuna Therapeutics, Strengthening Neuroscience Portfolio	NYSE:BMY	Bristol Myers Squibb Co
2024/03/16	07 : 27	Business Wire	FDA Advisory Committee Votes in Favor of Bristol Myers Squibb’s and 2seventy bio’s Abecma for Triple-Class Exposed Multiple Myeloma in Earlier Lines of Therapy	NYSE:BMY	Bristol Myers Squibb Co
2024/03/15	10 : 35	Business Wire	U.S. FDA Approves Bristol Myers Squibb’s Breyanzi® as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)	NYSE:BMY	Bristol Myers Squibb Co